Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT07740317 | Neurocognitive Trajectories After BCMA CAR-T(CAR-T Cog) | not yet recruiting | — | 50 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | not yet recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy(CARMic) | not yet recruiting | Phase 2 | 150 | Zealand University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842835 | Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB)(CLIMB) | not yet recruiting | — | 400 | Xiaohui RenOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07548450 | Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)(MPOWER) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07833046 | Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection | not yet recruiting | — | 40 | RenJi HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 28 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma(CAREMM-010) | not yet recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | not yet recruiting | Phase 1 | 108 | Canadian Myeloma Research GroupOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07828522 | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma(CAREMM-009) | not yet recruiting | Phase 2 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07823959 | CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma | not yet recruiting | — | 60 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07463976 | variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway(TITLE CLL) | not yet recruiting | — | 130 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07532473 | REal World MAIA UK OutcomEs(REMAKE) | not yet recruiting | — | 300 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)(ZEN-CLL) | not yet recruiting | Phase 2 | 95 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 204 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819214 | Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | not yet recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07776964 | Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) | not yet recruiting | N/A | 72 | University of MinnesotaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease(BEYOND-MM 001) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812246 | Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial | not yet recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy(BiFAST) | not yet recruiting | Phase 2 | 55 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07746232 | Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" | not yet recruiting | — | 92 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07808827 | A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 3 | 282 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | not yet recruiting | Phase 3 | 720 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07601100 | Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma(IsaIberVD) | not yet recruiting | Phase 1 / Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | not yet recruiting | Phase 2 | 50 | University of ArkansasOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma(TPG) | not yet recruiting | Phase 2 | 30 | Brown UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07791498 | Teclistamab In Waldenstrom's Macroglobulinemia | not yet recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03271632 | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06429150 | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789522 | Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma(HRMM-001) | not yet recruiting | Phase 2 | 15 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT04016129 | CAR-T Immunotherapy Targeting CD19- ALL | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04429438 | Multi-CAR-T Cells Targeting B Cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 11 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06006741 | Universal CAR-T Cells Targeting Multiple Myeloma | not yet recruiting | Phase 1 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07648459 | CM336-SOC for Dynamically High-Risk Multiple Myeloma Study(CAREMM-013) | not yet recruiting | Phase 2 | 46 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07508995 | A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07783607 | MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma(MM-CARE) | not yet recruiting | N/A | 33 | University of Vermont Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). | not yet recruiting | Phase 3 | 280 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07785505 | Musculoskeletal Ultrasound in Patients With Hematologic Malignancies | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Aug 25, 2026 | clinicaltrials |
| NCT06987708 | Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers | not yet recruiting | N/A | 67 | Hackensack Meridian HealthOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07615270 | A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | not yet recruiting | Early Phase 1 | 5 | Stanford UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 18 | BrightPath Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | Carrie Ho, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials